Effectiveness of Pharmacist Intervention on Capecitabine Relative Dose Intensity, Adherence, Knowledge & Safety Among Cancer Patients in Malaysia
NCT04175899 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 106
Last updated 2021-03-08
Summary
Over the past decade, oral administration of chemotherapy has significantly increased and is anticipated to continue to grow. Despite the conveniences, these oral regimens can be complex and pose challenge to patient adherence. Further safety concerns are warranted due to insufficient patient education, general perception of reduced toxicity with oral treatment, improper prescribing practice, and the lack of monitoring of observable adverse effects.
Therefore, effective medication counselling and patient education is vital to empower patients and their caregivers to increase adherence and safely managed medication to achieve optimal treatment outcome.
This study aims to evaluate the effectiveness of pharmacist intervention with structured oral chemotherapy education and patient monitoring on capecitabine treatment effectiveness (Relative Dose Intensity (RDI), Adherence and Persistence), safety outcomes (Adverse Event, Drug Related Problem and Health service utilization) and chemotherapy knowledge and self-efficiency among cancer patient care in Penang, a northern state oncology referral centre.
There are numerous published studies of pharmaceutical care implementations focusing mainly on in-patient setting and currently evolving in ambulatory cancer patients especially in western countries compared to Asian region. However systematic reviews show major gap still exist with paucity of scientific evidence on the effectiveness of therapeutic educational interventions for improving patient safety and adherence to oral chemotherapy mainly due to study design and method that are unable to strongly prove the outcome.
Hence highlighting the novelty and significance for this research using randomized controlled design, standardized \& validated tools for multimodal pharmacist intervention, long-term clinical outcome such as RDI with longitudinal assessment till treatment completion.
Conditions
- Solid Tumor, Adult
Interventions
- OTHER
-
Pharmacist-led Oral Chemo Care Program (POCCP)
Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment. Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare. It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols. Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients.
Sponsors & Collaborators
-
Universiti Sains Malaysia
collaborator OTHER -
Ministry of Health, Malaysia
lead OTHER_GOV
Principal Investigators
-
Balamurugan Tangiisuran, PhD · Universiti Sains Malaysia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-10
- Primary Completion
- 2021-11-30
- Completion
- 2021-11-30
Countries
- Malaysia
Study Locations
More Related Trials
-
Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy
NCT04327583 ·Status: UNKNOWN ·Phase: NA
-
Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events
NCT02733965 ·Status: UNKNOWN ·Phase: NA
-
The Food-effect on Alectinib Pharmacokinetics
NCT05710133 ·Status: COMPLETED ·Phase: NA
-
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Evaluate Systemic Bioavailability of Oral OTS167 in Healthy Adult Subjects
NCT02768519 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
NCT03459729 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Optimizing the Management of Patients With Oral Therapy
NCT03623490 ·Status: TERMINATED ·Phase: NA
-
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
NCT04663100 ·Status: RECRUITING ·Phase: NA
-
Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring
NCT01053104 ·Status: COMPLETED
-
Relationship of Nutritional Status to Chemotherapy Treatment Completion and Outcomes in Cancer Patients
NCT07059598 ·Status: COMPLETED
-
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00812864 ·Status: COMPLETED ·Phase: PHASE4
-
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
NCT01921140 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment
NCT04797143 ·Status: RECRUITING
-
Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
NCT03258099 ·Status: UNKNOWN
-
Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
NCT00733187 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors
NCT03257969 ·Status: RECRUITING ·Phase: NA
-
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer
NCT06469957 ·Status: COMPLETED
-
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
NCT00259935 ·Status: COMPLETED ·Phase: PHASE1
-
Collaborative Network to Take Responsibility for Oral Anticancer Therapy 2
NCT04142463 ·Status: UNKNOWN ·Phase: NA
-
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
NCT00465725 ·Status: COMPLETED ·Phase: PHASE1
-
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT05949424 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight
NCT01828554 ·Status: COMPLETED ·Phase: NA
-
Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer
NCT00875264 ·Status: COMPLETED ·Phase: PHASE1
-
Antineoplastic Drugs in Elderly Patients
NCT05467189 ·Status: RECRUITING
-
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
NCT04595851 ·Status: TERMINATED ·Phase: NA